TY - JOUR
T1 - Immunophenotyping assessment in a COVID-19 cohort (IMPACC)
T2 - A prospective longitudinal study
AU - IMPACC Manuscript Writing Team
AU - IMPACC Network Steering Committee
AU - Rou-Phael, Nadine
AU - Maecker, Holden
AU - Montgomery, Ruth R.
AU - Diray-Arce, Joann
AU - Kleinstein, Steven H.
AU - Altman, Matthew C.
AU - Bosinger, Ste Ven E.
AU - Eckalbar, Walter
AU - Guan, Leying
AU - Hough, Catherine L.
AU - Krammer, Florian
AU - Langelier, Charles
AU - Levy, Ofer
AU - McEnaney, Kerry
AU - Peters, Bjoern
AU - Rahman, Adeeb
AU - Rajan, Jayant V.
AU - Sigelman, Steven
AU - Steen, Hanno
AU - Van Bakel, Harm
AU - Ward, Alyssa
AU - Wilson, Michael R.
AU - Woodruff, Prescott
AU - Zamecnik, Colin R.
AU - Augustine, Alison D.
AU - Ozonoff, Al
AU - Reed, Elaine F.
AU - Becker, Patrice M.
AU - Higuita, Nelson Agudelo
AU - Altman, Matthew C.
AU - Atkinson, Mark A.
AU - Baden, Lindsey R.
AU - Becker, Patrice M.
AU - Bime, Christian
AU - Brakenridge, Scott C.
AU - Calfee, Carolyn S.
AU - Cairns, Charles B.
AU - Corry, David
AU - Davis, Mark M.
AU - Augustine, Alison D.
AU - Ehrlich, Lauren I.R.
AU - Haddad, Elias K.
AU - Erle, David J.
AU - Fernan-Dez-Sesma, Ana
AU - Hafler, David A.
AU - Kheradmand, Farrah
AU - Kleinstein, Steven H.
AU - Kraft, Monica
AU - Levy, Ofer
AU - Messer, William
N1 - Publisher Copyright:
© 2021 American Association for the Advancement of Science. All rights reserved.
PY - 2021/8
Y1 - 2021/8
N2 - The IMmunoPhenotyping Assessment in a COVID-19 Cohort (IMPACC) is a prospective longitudinal study designed to enroll 1000 hospitalized patients with COVID-19 (NCT04378777). IMPACC collects detailed clinical, laboratory and radiographic data along with longitudinal biologic sampling of blood and respiratory secretions for in depth testing. Clinical and lab data are integrated to identify immunologic, virologic, proteomic, metabolomic and genomic features of COVID-19-related susceptibility, severity and disease progression. The goals of IMPACC are to better understand the contributions of pathogen dynamics and host immune responses to the severity and course of COVID-19 and to generate hypotheses for identification of biomarkers and effective therapeutics, including optimal timing of such interventions. In this report we summarize the IMPACC study design and protocols including clinical criteria and recruitment, multi-site standardized sample collection and processing, virologic and immunologic assays, harmonization of assay protocols, high-level analyses and the data sharing plans.
AB - The IMmunoPhenotyping Assessment in a COVID-19 Cohort (IMPACC) is a prospective longitudinal study designed to enroll 1000 hospitalized patients with COVID-19 (NCT04378777). IMPACC collects detailed clinical, laboratory and radiographic data along with longitudinal biologic sampling of blood and respiratory secretions for in depth testing. Clinical and lab data are integrated to identify immunologic, virologic, proteomic, metabolomic and genomic features of COVID-19-related susceptibility, severity and disease progression. The goals of IMPACC are to better understand the contributions of pathogen dynamics and host immune responses to the severity and course of COVID-19 and to generate hypotheses for identification of biomarkers and effective therapeutics, including optimal timing of such interventions. In this report we summarize the IMPACC study design and protocols including clinical criteria and recruitment, multi-site standardized sample collection and processing, virologic and immunologic assays, harmonization of assay protocols, high-level analyses and the data sharing plans.
UR - http://www.scopus.com/inward/record.url?scp=85112833484&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112833484&partnerID=8YFLogxK
U2 - 10.1126/sciimmunol.abf3733
DO - 10.1126/sciimmunol.abf3733
M3 - Article
C2 - 34376480
AN - SCOPUS:85112833484
SN - 2470-9468
VL - 6
JO - Science Immunology
JF - Science Immunology
IS - 62
M1 - eabf3733
ER -